國藥控股(01099.HK):上半年歸母淨利潤34.66億元 同比下降6.43%
格隆匯8月25日丨國藥控股(01099.HK)發佈公吿,2025年上半年,集團實現營業收入人民幣2860.43億元,較去年同期下降2.95%;淨利潤及歸母淨利潤分別為人民幣53.37億元及34.66億元,同比下降分別為9.53%及6.43%。上半年,順應新的行業環境和政策監管要求,集團積極挖掘渠道協同和衍生服務的業務增長動能,進一步樹立價值驅動理念,加強盈利能力和現金回款等核心業務指標考核,各主要板塊業務收入的同比增速呈現差異化表現。其中,醫藥分銷板塊基本維持穩定發展,板塊收入佔比同比下降0.48個百分點,達到73.62%;器械分銷收入規模有所下降,板塊收入佔比同比略升0.08個百分點,達到19.22%;醫藥零售板塊呈現逆勢增長態勢,板塊收入佔比同比增長0.36個百分點,為5.78%。
報吿期內,集團費用管控成效凸顯,受益於融資成本降低、一體化管控舉措和業務成本的下降,銷售費用率、管理費用率及財務費用率持續下降,分別為2.74%、1.28%和0.35% ,三項費用率合計優化0.2個百分點,為收窄利潤下降提供有力支撐。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.